Nahid Ali , Ph.D, FTWAS, FNA, FASc, FNASc, FAScT, J C Bose National Fellow

J. C. Bose fellow , INSA Emeritus scientist
Infectious Diseases and Immunology

Research Interest

  • Diagnosis of Visceral Leishmaniasis (VL) and Post Kala-Azar Dermal Leishmaniasis (PKDL) 
  • Liposome based combination therapy with existing drugs or novel compounds
  • Designing novel drug and vaccine strategies against VL.
  • Study of host pathogen interaction in VL.
  • Development novel strategies and formulations for targeting cancer. 
  • Understanding the complex role of the immune system in the progression of cancer .
  • Designing novel checkpoint inhibitor formulations against the impaired immune system in cancer. 


  2. J C Bose National Fellow
  3. PhD, Calcutta University, 1985
  4. Prof, AcSIR
  5. Former Chief Scientist IICB
  6. Former HOD IDI Division IICB 

Honours & Awards

  1. 1989- UNDP Fellowship, NIH, USA.
  2. 2005- Member of the Molecular Immunology Forum (MIF).
  3. 2006- Prof. A. N. Bhaduri Memorial Lecture Award from the Society of Biological Chemists (India).
  4. 2012- Nodal Scientist of CSIR-Network project entitled “Host interactome analysis: understanding the role of host molecules in parasitic infection (HOPE)”, India.
  5. 2015- ‘J.C. Bose Fellowship Award’ from the Govt. of India, Ministry of Science & Technology, Department of Science and Technology, New Delhi.
  6. 2015-Top 10 Innovators Award for dipstick technology by DST Lockheed Martin India Innovation Growth Programme, New Delhi.
  7. 2015- Top 10 Innovators Award for dipstick technology jointly by FICCI, DST (Govt. of India) and Lockheed Martin Corporation, Indo-US Science and Technology Forum, Stanford Graduate School of Business, IC2 Institute, University of Texas at Austin and TiE Silicon Valley, New Delhi.
  8. 2016-‘INSA Senior Scientist Position’ from the Indian National Science Academy-Council, New Delhi.
  9. 2016- ‘Raja Ramanna Fellowship (RPF) Track-1 Award’ from the Govt. of India, Department of Atomic Energy, Mumbai .
  10. 2017- “WorldLeish6 Award” from the WL6 Scientific Community, in partnership with PLOS at 6th World Congress on Leishmaniasis (WL6), Toledo, Spain.
  11. 2017- Hub Lead India of MRC-Global Challenge Research Fund (GCRF) capacity Award on Project entitled “A Global Network for Neglected Tropical Disease”, UK.
  12. 2018-‘National Women Bioscientist Award (Senior Category) 2014, from Dr. Harsh Vardhan, Hon’ble Minister of Science & Technology and Earth Sciences, New Delhi.
  13. 2018-‘INSA Emeritus Scientist’ position from the Indian National Science Academy-Council, New Delhi.

Patents & Publications

  1. Kamran M, Bhattacharjee R, Das S, Mukherjee S, Ali N.2023. The paradigm of intracellular parasite survival and drug resistance in Leishmanial parasite through genome plasticity and Epigenetics: Current Insights and Future Perspective. Frontiers in Cellular and Infection Microbiology-Parasite and Host.13:1001973
  2. Das S, Mukherjee S, Ali N.2023. Purification of immune-active macrophage super enhancers by chemical cross-linked chromatin immune precipitation. STAR Protocol. 2023 Jan 11;4(1):102004. doi:10.1016/j.xpro.2022.102004.
  3. Sukla S., Nath H., Kamran M., Ejazi SA., Ali N. 2022. Das P., Ravichandiran V., Roy S., Biswas S. Detection of Leptomonasseymourinarna‑like virus in serum samples of visceral leishmaniasis patients and its possible role in disease pathogenesis. Scientific Reports.12:14436 
  4. Deepachandi B., Ejazi SA., Bhattacharyya A., Ali N. 2022. Soysa P., Siriwardana Y.,* Measuring the sero-prevalence of Leishmania donovani induced cutaneous  leishmaniasis: A method comparison study.Parasitology International. 92,102660 
  5. Ejazi SA., Saha S, Bhattacharyya A., Das S., Mateus NLF., Lima- MSDC., Abreu HCN.,  de Mendonca IL, Costa HCN., Melo OAO., de Melo MA., Bergmann BR., Corso R., Manna L., Ali N. 2022. Development of immunological assays  based on Leishmania donovani antigen for diagnosis of canine visceral leishmaniasis and their multicenter  evaluation in Brazil and Italy. Frontiers Cellular and Infection Microbiology. 2022 Jul 1;12:914477. doi: 10.3389/fcimb.2022.914477. 
  6. Kumar A, Ladha A, Choudhury A, Ikbal AMA, Bhattacharjee B, Das T, Gupta G, Sharma C, Sarbajna A, Mandal SC, Choudhury MD, Ali N, Slama P, Rezaei N, Palit P, Tiwari ON. 2022. The chimera of S1 and N proteins of SARS-CoV-2: can it be a potential vaccine candidate for COVID-19? Expert Rev Vaccines. May 31:1-16. 
  7. Gupta AK, Das S, Kamran M, Ejazi SA, Ali N. 2022. The pathogenicity and virulence of Leishmania - interplay of virulence factors with host defenses. Virulence. Dec;13(1):903-935. 
  8. Bhattacharyya A, Kamran M, Ejazi SA, Das S, Didwania N, Bhattacharjee R, Rahaman M, Goswami RP, Pandey K, Das VNR, Das P, Gayen S, Ali N. 2022. Revealing a Novel Antigen Repressor of Differentiation Kinase 2 for Diagnosis of Human Visceral Leishmaniasis in India. Pathogens. Jan 20;11(2):120. 
  9. Das, A., Kamran, M., and Ali, N. 2021. HO-3867 induces ROS-dependent stress response and apoptotic cell death in Leishmania donovani. Frontiers in Cellular and Infection Microbiology. Dec 3;11:774899. 
  10. Chakraborty, A., Banerjee, S., Mukherjee, B., Poddar, MK., Ali, N. 2021. Calorie restriction modulates Neuro-immune system differently in young and aged rats. International Immunopharmacology. 100:108141. doi:10.1016/j.intimp.2021.10814 
  11. Das, A., Ali, N. 2021. Nanovaccine: an emerging strategy. Expert Review of Vaccines. 2021;20(10):1273-1290. 
  12. Asad, M., Sabur, A., Kamran, M., Shadab, M., Das, S., Ali, N. 2021. Effector functions of Th17 cells are regulated by IL-35 and TGF-β in visceral leishmaniasis. FASEB J. 35(9):e21755. 
  13. Ejazi, SA., Choudhury, ST., Bhattacharyya, A., Kamran, M., Pandey, K., Das, VNR., Das, P., da, Silva, FO., Costa, DL., Costa, CHN., Rahaman, M., Goswami, RP., Ali, N. 2021. Development and Clinical Evaluation of Serum and Urine-Based Lateral Flow Tests for Diagnosis of Human Visceral Leishmaniasis.  Microorganisms. 2021;9(7):1369. 
  14. Kamran, M., Ejazi, SA., Choudhury, ST., Bhattacharyya, A., Tanishka, K., Pandey, K., Das, VNR., Das, P., da Silva, FO., Costa, DL., Costa, CHN., Rahaman, M., Goswami, RP., Ali, N. 2021.  A novel antigen, otubain cysteine peptidase of Leishmania donovani improves serodiagnosis of visceral leishmaniasis and monitors treatment response. Clinical Infectious Diseases. 73(7):1281-1283. 
  15. Das, S., Mukherjee, S., Ali, N. 2021. Super enhancer-mediated transcription of miR146a-5p drives M2 polarization during Leishmania donovani infection. PLoS Pathogens. 17(2). 
  16. Didwania N, Ejazi SA, Chhajer R, Sabur A, Mazumder, S., Kamran, M., Kar, R., Pandey, K., Das, V., Das, P., Rahaman, M., Goswami, RP., & Ali, N. 2020. Evaluation of cysteine protease C of Leishmania donovani in comparison with glycoprotein 63 and elongation factor-1α for diagnosis of human visceral leishmaniasis and for post-treatment follow-up response. Journal of Clinical Microbiology. 58(11). 
  17. Ali, N., Cobb, SL., & Mowbray, C. 2020. Introduction to the themed collection on ‘Neglected tropical diseases. RSC Medicinal Chemistry, 11, 1098–1099. 
  18. Kamran, M., Ejazi, SA., Bhattacharyya, A., Didwania, N., Ali, N.. 2020. A Native 51 kDa Leishmania membrane protein revealed as a novel antigenic candidate for immuno-diagnosis of human VL and PKDL diseases. Journal of Cellular Immunology. 2(6):301-307. 
  19. Ejazi, SA., Ghosh, S., Ali, N. 2020 Antibody detection assays for COVID-19 diagnosis: an early overview. Immunology & Cell Biology. 99(1):21-33 
  20. Ejazi SA, Ghosh S, Bhattacharyya A, Kamran M, Das S, Bhowmick S, Rahaman M, Goswami RP, Ali N. 2020. Investigation of the antigenicity and protective efficacy of Leishmania promastigote membrane antigens in search of potential diagnostic and vaccine candidates against visceral leishmaniasis. Parasites & Vectors. 13(1):272. 
  21. Das, S., Banerjee, A., Kamran, M., Ejazi, SA., Asad, M., Ali N, Chakrabarti S. 2020. A chemical inhibitor of heat shock protein 78 (HSP78) from Leishmania donovani represents a potential antileishmanial drug candidate. Journal of Biological Chemistry. 295(29):9934-9947. 
  22. De, M, Ghosh, S., Asad, M., Banerjee, I., Ali, N. 2020. Combining doxorubicin with stearylamine-bearing liposomes elicits Th1 cytokine responses and cures metastasis in a mouse model. Cancer Immunology, Immunotherapy. 69(9):1725-1735. 
  23. Ejazi, SA., Ghosh, S., Saha, S., Choudhury, ST., Bhattacharyya, A., Chatterjee, M., Pandey, K., Das,V.N.R., Das, P., Rahaman, M., Goswami, RP., Rai, R., Khanal, B.,  Bhattarai, N., Deepachandi, B., Siriwardana, Y., Karunaweera, N. D.,  deBrito, M. E. F.,  MirandaGomes, Y. D., Nakazawa, M., Costa, C.H.N., Adem, E., Yeshanew, A.,  Melkamu, R., Fikre, H., Hurissa, Z., Diro, E., Carrillo, E., Moreno, J. & Ali. N. 2019. A multicentric evaluation of dipstick test for serodiagnosis of visceral leishmaniasis in India, Nepal, Sri Lanka, Brazil, Ethiopia and Spain. Scientific Reports. 9:9932 1-7. 
  24. Asad, M., Sabur, A., Shadab, M., Das, S., Kamran, M., Didwania, N., Ali, N. 2019. EBI-3 chain of IL-35 along with TGF-B synergistically regulate anti-leishmania Immunity. Frontiers in Immunology (10) 1-12 
  25. Shadab, M., Das, S., Banerjee, A., Sinha, R., Asad, M., Kamran, M., Maji, M., Jha, B., Deepthi, m., Kumar, M., Tripathi, A., Kumar, B., Chakrabarti, S., Ali, N. 2019. RNA-Seq Revealed Expression of many Novel Genes associated with Leishmania donovani Persistence and Clearance in the Host Macrophage. Frontiers in Cellular and Infection Microbiology (9) 1-19. 
  26. Banerjee I , De M , Dey G , Bharti R , Chattopadhyay S , Ali, N , Chakrabarti P , Reis RL , Kundu SC , Mandal M., 2019. A peptide-modified solid lipid nanoparticle formulation of paclitaxel modulates immunity and  outperforms dacarbazine in a murine melanoma model. Biomaterial Science. 26; 7(3):1161-1178. 
  27. Ejazi SA, Bhattacharyya A, Choudhury ST, Ghosh S, Sabur A, Pandey K, Das VNR, Das P, Rahaman M, Goswami RP, Ali N. 2018. Immunoproteomic identification and characterization of Leishmania membrane proteins as non-invasive diagnostic candidates for clinical visceral leishmaniasis. Scientific Reports  8(1):12110. 
  28. Das, A., Asad, M., Sabur, A., Didwania, N., and Ali, N. 2018.  Monophosphoryl lipid A based cationic liposome facilitates vaccine induced expansion of polyfunctional t cell immune responses against visceral leishmaniasis. ACS Applied Bio Materials. 1, 999−1018. 
  29. Sinha, R., Malar, M., Kumar, R., Das, S., Das, S., Shadab, M., Chowdhury, R., Tripathy, S., and Ali, N. 2018. Genome plasticity in cultured Leishmania donovani: Comparison of early and late passages. Frontiers in Microbiology. 9:1279, 1-20. 
  30. Palit, P., Mukherjee, D., Mahanta, P., Shadab, M., Ali, N., Roychoudhury, S., Asad, M., Mandal, SC. 2018. Attenuation of nociceptive pain and inflammatory disorders by total steroid and terpenoid fraction of Euphorbia tirucalli Linn root in experimental in vitro and in vivo model. Inflammopharmacology. 26(1):235- 250. 
  31. Sabur, A., Bhowmick, S., Chhajer, R., Ejazi, SA., Didwania, N., Asad, M., Bhattacharyya, A., Sinha, U., Ali N. 2018. Liposomal EF1-α triggers multifunctional T cells for induction of long lasting protective immunity against VL. Frontiers in Immunology. 9(18) 1-14. 
  32. De, M., Ghosh, S., Sen, T., Shadab, M., Banerjee, I., Basu, S., and Ali, N. 2018. A Novel  therapeutic strategy for cancer using phosphatidylserine targeting stearylamine-bearing cationic liposomes. Molecular Therapy – Nucleic Acids. (10) 9-27. 
  33. De M, Ghosh S, Sen T, Shadab M, Banerjee I, Basu S, Ali N. A Novel Therapeutic Strategy for Cancer Using Phosphatidylserine Targeting Stearylamine-Bearing Cationic Liposomes. Mol Ther Nucleic Acids. 2018 Mar 2;10:9-27. doi: 10.1016/j.omtn.2017.10.019. Epub 2017 Nov 1.
  34. Sabur A, Bhowmick S, Chhajer R, Ejazi SA, Didwania N, Asad M, Bhattacharyya A, Sinha U, Ali N. Liposomal Elongation Factor-1α Triggers Effector CD4 and CD8 T Cells for Induction of Long-Lasting Protective Immunity against Visceral Leishmaniasis. Front Immunol. 2018 Jan 30;9:18. doi: 10.3389/fimmu.2018.00018. eCollection 2018.
  35. Didwania N, Shadab M, Sabur A, Ali N. Alternative to Chemotherapy-The Unmet Demand against Leishmaniasis. Front Immunol. 2017 Dec 21;8:1779. doi: 10.3389/fimmu.2017.01779. eCollection 2017. Review.
  36. Palit P, Mukherjee D, Mahanta P, Shadab M, Ali N, Roychoudhury S, Asad M, Mandal SC. Attenuation of nociceptive pain and inflammatory disorders by total steroid and terpenoid fraction of Euphorbia tirucalli Linn root in experimental in vitro and in vivo model. Inflammopharmacology. 2018 Feb;26(1):235-250. doi: 10.1007/s10787-017-0403-7. Epub 2017 Oct 23.
  37. Shadab M, Jha B, Asad M, Deepthi M, Kamran M, Ali N. Apoptosis-like cell death in Leishmania donovani treated with KalsomeTM10, a new liposomal amphotericin B. PLoS One. 2017 Feb 7;12(2):e0171306. doi: 10.1371/journal.pone.0171306. eCollection 2017.
  38. Ejazi SA, Bhattacharya P, Bakhteyar MA, Mumtaz AA, Pandey K, Das VN, Das P, Rahaman M, Goswami RP, Ali N. Noninvasive Diagnosis of Visceral Leishmaniasis: Development and Evaluation of Two Urine-Based Immunoassays for Detection of Leishmania donovani Infection in India. PLoS Negl Trop Dis. 2016 Oct 14;10(10):e0005035. doi: 10.1371/journal.pntd.0005035. eCollection 2016 Oct.
  39. Bhattacharya P, Ali N. Treatment of visceral leishmaniasis: anomalous pricing and distribution of AmBisome and emergence of an indigenous liposomal amphotericin B, FUNGISOME. J Parasit Dis. 2016 Sep;40(3):1094-5. doi: 10.1007/s12639-014-0607-3. Epub 2014 Nov 1.
  40. Sabur A, Asad M, Ali N. Lipid based delivery and immuno-stimulatory systems: Master tools to combat leishmaniasis. Cell Immunol. 2016 Nov;309:55-60. doi: 10.1016/j.cellimm.2016.07.011. Epub 2016 Jul 21. Review.
  41. Chhajer R, Bhattacharyya A, Didwania N, Shadab M, Das N, Palit P, Vaidya T, Ali N. Leishmania donovani Aurora kinase: A promising therapeutic target against visceral leishmaniasis. Biochim Biophys Acta. 2016 Sep;1860(9):1973-88. doi: 10.1016/j.bbagen.2016.06.005. Epub 2016 Jun 8.
  42. Choudhury ST, Das N, Ghosh S, Ghosh D, Chakraborty S, Ali N. Vesicular (liposomal and nanoparticulated) delivery of curcumin: a comparative study on carbon tetrachloride-mediated oxidative hepatocellular damage in rat model. Int J Nanomedicine. 2016 May 18;11:2179-93. doi: 10.2147/IJN.S101886. eCollection 2016.
  43. Dar AA, Shadab M, Khan S, Ali N, Khan AT. One-Pot Synthesis and Evaluation of Antileishmanial Activities of Functionalized S-Alkyl/Aryl Benzothiazole-2-carbothioate Scaffold. J Org Chem. 2016 Apr 15;81(8):3149-60. doi: 10.1021/acs.joc.6b00113. Epub 2016 Apr 6.
  44. Bhattacharya P, Ghosh S, Ejazi SA, Rahaman M, Pandey K, Ravi Das VN, Das P, Goswami RP, Saha B, Ali N. Induction of IL-10 and TGFβ from CD4+CD25+FoxP3+ T Cells Correlates with Parasite Load in Indian Kala-azar Patients Infected with Leishmania donovani. PLoS Negl Trop Dis. 2016 Feb 1;10(2):e0004422. doi: 10.1371/journal.pntd.0004422. eCollection 2016 Feb
  45. Dar AA, Enjamuri N, Shadab M, Ali N, Khan AT. Synthesis of Unsymmetrical Sulfides and Their Oxidation to Sulfones to Discover Potent Antileishmanial Agents. ACS Comb Sci. 2015 Nov 9;17(11):671-81. doi: 10.1021/acscombsci.5b00044. Epub 2015 Oct 19.
  46. Asad M, Bhattacharya P, Banerjee A, Ali N. Therapeutic and immunomodulatory activities of short-course treatment of murine visceral leishmaniasis with KALSOME™10, a new liposomal amphotericin B. BMC Infect Dis. 2015 Apr 17;15:188. doi: 10.1186/s12879-015-0928-6.
  47. Ali N, Nakhasi HL, Valenzuela JG, Reis AB. Targeted Immunology for Prevention and Cure of VL. Front Immunol. 2014 Dec 19;5:660. doi: 10.3389/fimmu.2014.00660. eCollection 2014.
  48. Sinha R, Roychoudhury J, Palit P, Ali N. Cationic liposomal-sodium  stibogluconate (SSG): A potent therapeutic tool for the treatment of SSG-sensitive and -resistant Leishmania donovani infection. Antimicrobial Agents and Chemotherapy, 2014, pii: AAC.03305-14. [Epub ahead of print].
  49. Das A. and Ali N. Combining cationic liposomal delivery with TLR4 ligand for cysteine protease cocktail vaccination against Leishmania donovani: evidence for antigen synergy and protection. PLOS Neglected Tropical Diseases. 2014, 8(8), 1-17.
  50. Chhajer R and Ali N. Genetically modified organisms and visceral leishmaniasis. Frontiers in Immunology, 2014, 5, 1-10.
  51. Md Asad and Ali N. Dynamicity of immune regulation during visceral leishmaniasis. Proc Indian National Science Academy, 80 No. 2 June 2014 pp.
  52. Bhowmick S, Ravindran R, Ali N. IL-4 contributes to failure, and colludes with IL-10 to exacerbate Leishmania donovani infection following administration of a subcutaneous leishmanial antigen vaccine. BMC Microbiology. 2014, 14, 1-12.
  53. Bhattacharya P, Ali N. Involvement and interactions of different immune cells and their cytokines in human visceral leishmaniasis. Revista da Sociedade Brasileira de Medicina Tropical, 2013, 46(2), 128-134.
  54. Ejazi SA, Ali N. Developments in diagnosis and treatment of visceral leishmaniasis during the last decade and future prospects. Expert Review of Anti-Infective Therapy, 2013, 11(1), 79-98.
  55. Das A and Ali N. Vaccine development against Leishmania donovani. Frontiers in Microbial Immunology, 2012, 3,1-19.
  56. Palit P, Hazra A, Maity A, Vijayan RS, Manoharan P, Banerjee S, Mondal NB, Ghoshal N, Ali N. Discovery of safe and orally effective 4-aminoquinaldine analogues as apoptotic inducers with activity against experimental visceral leishmaniasis. Antimicrobial Agents and Chemotherapy, 2012, 56, 432-445.
  57. Ravindran R, Maji M, Ali N.  Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route. Molecular Pharmaceutics, 2012, 9, 59-70.
  58. Mazumder S, Maji M and Ali N. Potentiating effects of MPL on DSPC bearing cationic liposomes promote recombinant GP63 vaccine efficacy: high immunogenicity and protection. PLoS Neglected Tropical Diseases, 2011, 5, 1-13.
  59. Palit P, Hazra A, Maity A, Vijayan RS, Manoharan P, Banerjee S, Mondal NB, Ghoshal N, Ali N. Discovery of safe and orally effective 4-aminoquinaldine analogues as apoptotic inducers with activity against experimental visceral leishmaniasis. Antimicrobial Agents and Chemotherapy, 2012, 56, 432-445.
  60. The Working Group on Research Priorities for Development of Leishmaniasis VaccinesCosta CHPeters NC, Ali N, Maruyama SRde Brito EC JrSantos IK. Vaccines for the leishmaniases: proposals for a research agenda.  PLos Neglected Tropical Diseases, 2011, 5(3), 1-9.
  61. Saha S,  Goswami R, Pramanik N, Guha SK, Saha B, Rahman M, Mallick S, Modak  D, Silva FO, Mendonca IL, Costa DL, Costa CHN, and Ali N. Development and evaluation of Leishmania donovani Promastigote membrane antigen-based serodiagnosis of visceral leishmaniasis and post Kala-azar dermal leishmaniasis. Emerging Infectious Diseases, 2011, 17, 1304-1306.
  62. Mazumder, S, Maji M, Das, A and Ali N. Potency, efficacy and durability of DNA/DNA, DNA /protein and protein/protein based vaccination using gp63 against Leishmania donovani in BALB/c Mice. PLoS ONE, 2011, 6, 1-15.
  63. Banerjee, A., De, M., and Ali N. Combination therapy with paromomycin associated stearylamine-bearing liposomes cures experimental visceral leishmaniasis through Th1-biased immunomodulation. Antimicrobial Agents and Chemotherapy, 2011, 55, 1661-1670.
  64. Mondal S, Bhattacharya P and Ali N. Current diagnosis and treatment of visceral leishmaniasis. Expert Review on Anti-Infective Therapy, 2010, 8, 919-944.
  65. Mondal S, Bhattacharya P, Rahaman M, Ali N and Goswami R. P. A curative immune profile one-week after treatment of Indian kala-azar patients predicts success with short-course liposomal amphotericin B therapy. PLos Neglected Tropical Diseases, 2010, 4, 1-8.
  66. Sinha R, Sengupta A, Ali N and Gupta P. N. Is PGL-I really a specific antigen for leprosy? Clinical Infectious Diseases, 2010, 50, 937-938.
  67. Bhowmick SMazumdar TSinha R and Ali N. Comparison of liposome based antigen delivery systems for protection against Leishmania donovani. Journal of Controlled Release, 2010, 141, 199-207.
  68. Bhowmick S., and Ali N. Identification of novel Leishmania donovani antigens that help define correlates of vaccine-mediated protection in visceral leishmaniasis. PLoS ONE. 2009, 4, 1-10.
  69. Banerjee A., De M., and Ali N.  Complete cure of experimental visceral leishmaniasis with amphotericin B in stearylamine-bearing cationic liposomes involves down-regulation of IL-10 and favorable T cell responses. Journal of Immunology, 2008, 181, 1386-1398.
  70. Bhowmick S., and Ali N. Recent developments in leishmaniasis vaccine delivery systems. Expert Opinion on Drug Delivery. 2008, 7, 789-803.
  71. Banerjee A., Roychoudhury J., and Ali N. Stearylamine-bearing cationic liposomes kill Leishmania parasites through surface exposed negatively charged phosphatidylserine. Journal of Antimicrobial Chemotherapy, 2008, 61, 103-110.
  72. Palit P., and Ali N. Oral Therapy with Amlodipine and Lacidipine, 1, 4-Dihydropyridine Derivatives Showing Activity against Experimental Visceral Leishmaniasis. Antimicrobial Agents Chemotherapy. 2008, 52, 374-377.
  73. Saha, S., Mondal, S., Ravindran, R., Bhowmik, S., Modak, D., Mallick, S., Rahman, M., Kar, S., Goswami, R., Guha, SK., Pramanik, N., Saha, B., Ali N. IL-10 and TGF-β mediated susceptibility in Post-kala-azar-dermal leishmaniasis: The significance of amphotericin B in the control of Leishmania donovani infection in India. Journal of Immunology, 2007, 179, 5592-5603.
Patents Granted: :
  1. Ali, N., Ghose, J., and Bhowmik. S. Novel cationic liposomal formulations and    process for making such formulations. Application No: 1339/DEL/2005; Prov.Filing Date: 25/05/2005; Comp. Filing date 24/05/2006; Grant Date 26/04/2013; Patent Number 256052.
  2. Ali, N., and Banerjee, A. “Antileishmanial activity of amphotericin B entrapped in  cationic liposomal formulation”. Application No: 0670/DEL/2007; Filing Date 28/03/2007; Comp. Filing date 28/03/2007; Grant Date 22/01/2015; Patent Number 264798.
  3. Ali, N., and Banerjee, A. “Antileishmanial activity of paramomycin entrapped in cationic liposomal formulations.” Application No: 1180/DEL/2007; Filing Date 01/06/2007.
  4. Ali, N., and Das, A. “A DNA vaccine formulation in cationic liposome vehicle useful for maximising vaccine potency for leishmaniasis.” Application No.  3864/DEL/2014; NFNO No. 0132NF2013/IN; Complete Filing Date 23/Dec/2014; Patent No. 394792; Grant date: 13/04/2022.
  5. Ali,N, De, M., Sen, T. “Anti-cancer activity of stearylamine bearing cationic liposomal drug ormulations.” PCT Application No.: PCT/IN2014/000610; Prov. Filing Date: 18/09/2014. EU Patent No.3046542, Dated 06.01.21
  6. Bandyopadhyay S., Ghosh B., Jaisankar P., Pal B.C., Roy S., Pal B., Ram A., Mabalirajan U., Ali N., Bandyopadhyay A., Konar A., Chakraborty J.B., Mukherjee I.C., Chaudhuri J., Mahato S.K., Manna A., Sinha R., Bhattacharya P., Vinayagam J., Jana D.P., Chowdhury S. Substituted catechols as inhibitors of IL-4 and IL-5 for the treatment of bronchial asthma. Application no.: PCT/IB2012/051757. Filed on:11/04/2012. Publication nos.: WO2012140574 A1 (Published on: 18/10/2012) and US20140135393 A1 (Published on: 15/05/2014).


Chapters in books::
  1. Anam, K., Pramanik, N., Guha S. K., Goswami, R. P., Gupta, P. N., Banerjee, D., Saha, S. K., and Ali, N. Immunodiagnosis of kala azar. In, Strategies for Control of Kala azar and Malaria. Proceedings of WHO Workshop, Dec 27-28, 2001. Ed. S. K. Bhattacharya, Balaji UthanSansthan, Patna.
  2. Ejazi, S.A, and Ali, N. Visceral Leishmaniasis: Immune Mechanisms and New Insights in Vaccine Development and Control In, Neglected Tropical Diseases in Middle East and North Africa (MENA). Ed M. A. McDowell and S. Rafati, Springer-Verlag Wien, New York, USA; 2014. 141-171.
  3. Sabur, A., and Ali, N. Vaccine Biology of Leishmania Infection. In Leishmania: Current Biology and Control. Ed S. Adak and R. Datta, Caister Academic Press, UK; January, 2015. 10:167-192.
  4. Chakraborty, J., Sabur, A., Ali, N., and Goswami R.P., Visceral Leishmaniasis: a Current Problems and Prospect of an Effective Vaccine. In Adult Immunization 2014. Ed A. Muruganathan, D. Mathai and S. K. Sharma, Association of Physicians of India; 2014. 34:254-259.
  5. Sinha, R., Ali, N. Molecular Biology of Kinetoplastid Parasites, Caister Academic Press, United Kingdom. Chapter 9 Pre-adaptation of Leishmania Promastigotes to Intracellular Life: Ensuring a Successful Infection. 2017. 137.
  6. Kwang Poo Chang, Bala K. Kolli, Ali, N and collaborates. Overview of leishmaniasis with special emphasis on kala-azar in South Asia. In Neglected Tropical Diseases - South Asia. Springer International Publishing AG 2018. 1-63.
  7. Bhattachchrya, A, Gayen, S, Ali, N. Recombinant antigens: Promissing markers for therapy and diagnosis of leishmaniasis. In Recent Trends In Microbiology (Vol-I). 2022. 143-158.Published by Santanu Banerjee, Scholar, Book hub, Kolkata.